Another giant leap for Nova Leap as they record a 685% EBITDA year on year increase in Q3, 2019

Investors should put this home health care stock on the top of their watch list before it moves even higher. The Company has now achieved nine consecutive quarters of revenue growth, and as a result the stock is up 38% in the last six months, and 58% in the last three months. Even better for investors is that this Canadian gem is still very cheap with a market cap of just C$ 23 million, due to the early stage of the Company. It operates in the booming US and Canadian health care sectors, in the in-demand area of home health care.

Nova Leap stock price surges higher on strong growth

The stock is Nova Leap Health Corp. (TSXV: NLH) and it is based in Nova Scotia, Canada. Nova Leap acquires, manages, and builds home care service companies. Nova Leap is geographically diversified with operations in 5 different U.S. states: Vermont, New Hampshire, Massachusetts, Rhode Island and Oklahoma as well as Nova Scotia, Canada.

Just released last week their Q3, 2019 financial results were a record for the Company, reporting a 685% EBITDA increase over the same quarter in 2018. Q3, 2019 EBITDA of US$324,676 increased 49.2% over Q2 2019 EBITDA of US$217,549. And the giant leaps don’t stop there, the Company achieved over US$4.4 million in Q3, 2019 revenue, the nine consecutive quarter of revenue growth.

Nova Leap President & CEO Chris Dobbin stated: “Third quarter results were the best in our Company’s history. From a financial perspective, our focus remains on cash flow growth in existing operations and the deployment of free cash flow to high return potential opportunities.”

Nova Leap achieves nine consecutive quarters of revenue growth

Nova Leap has acquired Keystone Homecare and Around The Clock Home Care

Nova Leap continues to acquire small home care businesses and has announced their latest acquisition in Massachusetts. Previously announced on September 25, 2019, Nova Leap has now completed the acquisition of the business assets of Keystone Homecare LLC, located in Stow, Massachusetts.

This news is a follow up to the announcement the Company made in early October on the completed acquisition of the business assets of Around The Clock Home Care, located in Chickasha, Oklahoma. It’s noted that these two latest acquisitions in Oklahoma and Massachusetts, were not reflected in the Q3 results. These are just two recent examples of the Company’s rapid expansion.

Nova Leap is steadily moving up the rankings

Nova Leap achieved the #10 ranking in the 2019 TSX Venture 50™ in the Clean Technology & Life Sciences sector. Announced on September 2019, Nova Leap now ranks at number 4 on the 2019 Canadian Business and Maclean’s Start-up 50 ranking of Canada’s Top New Growth Companies.

Nova Leap’s business model

Nova Leap’s model of success is acquiring small home care businesses in Canada and the US. Combined these small businesses are forming the beginning of what the Company believes will be a large international organization. As the business scales up margins are improving, helped by reduced head office costs as a percentage of revenue. For example, head office costs as a percentage of revenue have fallen from 53% in 2017, to 5.6% in Q3 2019. This trend demonstrates the Company’s ability to scale the business with existing personnel and infrastructure.

The criteria they follow is simple, a geographical focus on the US and Canada, a positive EBITDA with a strong reputation/brand, and ideally have a 10 year history with US$1 million plus in revenues.

Demographics are a strong tailwind for Nova Leap

An aging population in most western countries is requiring more and more home care. Each day in the US over 10,000 people are turning 65, and the baby boomer generation is retiring in droves. The non-medical home care market is a massive $5.4 billion dollar opportunity (6.1% of the $89.2 billion U.S. home health care market revenue).

Nova Leap sees massive opportunities ahead in acquiring established home health care facilities in safe countries. Home health care is a very fragmented industry with no major players having a dominant percentage of the market. Nova Leap strategy is to fill that role as the home care industry is one of the fastest growing industries in the U.S.A.

Nine consecutive quarters of revenue growth shows Nova Leap is really “leaping” ahead. Investors should also be reminded that the name ‘Nova’ means ‘a star that suddenly becomes thousands of times brighter’. The future looks very bright for Nova Leap Health Corp.




MI3 Market Alert: Rapid Pathogen detection system

Mario Drolet President of MI3 Communications Financières Inc. (MI3) released a technical note at market open today on LexaGene Holdings Inc. (TSXV: LXG | OTCQB: LXXGF) for exclusive distribution on InvestorIntel. In this note, MI3 highlighted the following points on LexaGene Holdings Inc.

  • LexaGene is a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing and biodefense.
  • LexaGene Places its First Beta Prototype into Massachusetts Veterinary Referral Hospital.
  • This placement marks a very significant milestone for the Company and for the diagnostics industry.
  • LXG close a 6.64 Million with Industrial Alliance securities
  • Support: S2; $ 0.45 – S1; $ 0.47     Resistance:   R1; $ 0.50 –   R2; $0.545

About LexaGene Holdings Inc.

LexaGene is a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing and biodefense. End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, enter sample ID and press ‘go’. The LX Analyzer delivers excellent sensitivity, specificity, and breadth of detection and can process multiple samples at a time, in an on-demand fashion, returning results in about 1 hour. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.

PLEASE DO YOUR DUE DILIGENCE

Disclaimer: This MI3 Technical Note produced by MI³ Communications Financières is neither an offer to sell, nor the solicitation of an offer to buy any of the securities discussed therein. The information contained is prepared by MI3, emanating from sources deemed to be reliable. MI3 Communications Financières makes no representations or warranties with respect to the accuracy, correctness or completeness of such information. MI³ Communications Financières accepts no liability whatsoever for any loss arising from the use of the information contained therein. Please take note that for compliance purposes, all directors, consultants or employees of MI3 Communications Financières are prohibited from trading the securities of the company and MI3 Communications Financières is a shareholder and do not intend to sell any shares during the distribution of this note.




Early identification of colon cancer blood test places healthcare in patients hands

In the news release announced this morning about one of the first blood tests to aid in the early identification of colorectal cancer, Chairman and CEO James Howard-Tripp of StageZero Life Sciences, Ltd. (TSX: SZLS) starts with “…patients want to control where their dollars go and they want to control how they get healthcare.”

In an interview with InvestorIntel’s Tracy Weslosky, James adds that “This is a way for them to get the tests done particularly for early cancer detection. We have been pushing into this quite strongly and we are starting to lift off. Last month we have had over a million impressions. That’s people to whom our ads have gone and who have looked at the ads. When that starts to translate there are those who would come and download information and give you more information. They also give you permission to engage with them all the way to those who would buy the test online…”

James went on to provide an update on StageZero’s entry into the European Market with Oncore Pharma as a licensing partner. Oncore Pharma, has signed a multi-year agreement with BodyCheck NL for the distribution and sale of StageZero’s  ColonSentry® throughout the Netherlands, Belgium and Luxembourg. The multi-year agreement is valued at US$40 million. James also said that StageZero is working with the firefighter population to improve early cancer detection and has become a go-to company for them. He said, “We can find ten cancers from a single sample of blood and we are way ahead of anyone else in terms of the science.”

To access the complete interview, click here

Disclaimer: StageZero Life Sciences, Ltd. is an advertorial member of InvestorIntel Corp.




MI3 Market Alert: Next generation pharmaceutical products for unmet medical needs

Mario Drolet President of MI3 Communications Financières Inc. (MI3) released a technical note at market open today on IntelGenx Technologies Corp. (TSXV: IGX | OTCQX: IGXT) for exclusive distribution on InvestorIntel. In this note, MI3 highlighted the following points on IntelGenx Technologies Corp.

  • IntelGenx’s superior film technologies, including VersaFilm®, VetaFilm™ and transdermal, allow for next generation pharmaceutical products that address unmet medical needs. IntelGenx’s innovative product pipeline offer significant benefits to patients and physicians for many therapeutic conditions.
  • IntelGennx is currently conducting scale-up activities for cannabis-infused oral film product for an anticipated commercial launch. With the recent Cannabis Act amendments authorizing the sale of new classes of cannabis products, including oral films, we are well-positioned participate in the expanded cannabis market just as new product formats come online.
  • Rebounding since 70 cents … next target $0.93 …Echelon Wealth Partners rate IGX at $1.60
  • Support: S2; $0.70    S1; $0.78   Resistance:   R1; $ 0.89    R2; $0.93

About IntelGenx:

IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.

IntelGenx’s superior film technologies, including VersaFilm®, VetaFilm™ and transdermal, allow for next generation pharmaceutical products that address unmet medical needs. IntelGenx’s innovative product pipeline offer significant benefits to patients and physicians for many therapeutic conditions.

IntelGenx’s highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx’s state-of-the-art manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production.

PLEASE DO YOUR DUE DILIGENCE

Disclaimer: This MI3 Technical Note produced by MI³ Communications Financières is neither an offer to sell, nor the solicitation of an offer to buy any of the securities discussed therein. The information contained is prepared by MI3, emanating from sources deemed to be reliable. MI3 Communications Financières makes no representations or warranties with respect to the accuracy, correctness or completeness of such information. MI³ Communications Financières accepts no liability whatsoever for any loss arising from the use of the information contained therein. Please take note that for compliance purposes, all directors, consultants or employees of MI3 Communications Financières are prohibited from trading the securities of the company and MI3 Communications Financières is a shareholder and do not intend to sell any shares during the distribution of this note.




Scott Spearn on MedX’s skin cancer screening in Brazil and Spain

“It is an incredible project for MedX and we are fortunate enough to be in a position we are with Brazil. It is a population of about 210 million people and they are facing a major skin cancer problem. Meaning that it is not being detected until the late stages. i.e. states 3 and 4. Our device will help the people of Brazil detect it at its early onset…We have an exclusive distribution partner in Brazil. We have 45 salespeople trained in the use of our SIAscope on DermSecureTM. We are looking at significant revenues over the next two or three quarters.” States Scott Spearn, President and CEO of MedX Health Corp. (TSXV: MDX), in an interview with InvestorIntel’s Tracy Weslosky.

Scott went on to provide an update on MedX’s operations in Spain. He said that the company is working with a large group and a number of national organizations in Spain. They have done 1368 patients counsels which involved 2475 scans which identified 9 melanomas. Scott also said that mobile apps are not effective in detecting skin cancers. MedX’s SIAscope takes five images and reaches two millimeters below the skin and then uploads to the DermSecureTM  software platform so that the images can be transmitted to a dermatologist for quick and early diagnosis. No other product does that.

To access the complete interview, click here

Disclaimer: MedX Health Corp. is an advertorial member of InvestorIntel Corp.




MI3 Market Alert: A leading oral drug delivery company with proprietary VersaFilm® technology

Mario Drolet President of MI3 Communications Financières Inc. (MI3) released a technical note at market open today on IntelGenx Corp.  (TSXV: IGX | OTCQX: IGXT) for exclusive distribution on InvestorIntel. In this note, MI3 highlighted the following points on IntelGenx Corp.

  • IntelGenx is a leading oral drug delivery company focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm® technology platform.
  • IntelGenx’s highly skilled team provides comprehensive pharmaceutical services to partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. Established for the VersaFilm® technology platform, IntelGenx’s state-of-the-art manufacturing facility supports lab-scale-to-pilot and commercial-scale production, offering full-service capabilities to our clients.
  • RSI AT 77. MACD … bullish … recent spike can indicate a catalyst is imminent!!!
  • Daily volume on the rise … IGX traded over 680 000 shares since Sept 2
  • Support: S2; $ 0.75    S1; $ 0.85   Resistance:   R1; $ 0.94     R2; $ 1.00

About IntelGenx:

IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.

IntelGenx’s superior film technologies, including VersaFilm®, VetaFilm™ and transdermal, allow for next generation pharmaceutical products that address unmet medical needs. IntelGenx’s innovative product pipeline offer significant benefits to patients and physicians for many therapeutic conditions.

IntelGenx’s highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx’s state-of-the-art manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production.

PLEASE DO YOUR DUE DILIGENCE

Disclaimer: This MI3 Technical Note produced by MI³ Communications Financières is neither an offer to sell, nor the solicitation of an offer to buy any of the securities discussed therein. The information contained is prepared by MI3, emanating from sources deemed to be reliable. MI3 Communications Financières makes no representations or warranties with respect to the accuracy, correctness or completeness of such information. MI³ Communications Financières accepts no liability whatsoever for any loss arising from the use of the information contained therein. Please take note that for compliance purposes, all directors, consultants or employees of MI3 Communications Financières are prohibited from trading the securities of the company and MI3 Communications Financières is a shareholder and do not intend to sell any shares during the distribution of this note.